Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Daily12h
Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...
Nasdaq2d
Gilead's Seladelpar Gets Conditional European Approval For Primary Biliary Cholangitis Treatment
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in ...
Nasdaq2d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
U.S. Indication for Livdelzi Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate ...
The Pharma Letter2d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
TheHealthSite6d
Everything To Know About Bile Duct Disorders: Signs, Symptoms, Causes, Treatment Options
Bile duct disorders can lead to serious complications if left untreated, but early diagnosis and proper management can prevent long-term damage, a doctor states. READ ON to find out more.
pharmaphorum5d
FDA clears Ipsen’s primary biliary cholangitis drug
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).